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Mucoepidermoid carcinoma of the maxillary sinus is a rare malignancy of the head and neck. The location of
this tumour near vital structures and its large size at presentation makes surgical resection with negative margins
challenging. In incurable cases, relief from symptoms such as epistaxis may be achieved with radiation therapy.
We present a case of mucoepidermoid carcinoma of the maxillary sinus that was effectively palliated with a short
course of radiation therapy, achieving complete cessation of bleeding, decrease in tumour size, and long term
control. We surveyed the literature on mucoepidermoid carcinomas and propose that some tumours may be
particularly radiosensitive, benefiting from even short courses of radiation therapy.
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Paranasal sinus malignancies account for 3-5% of all head
and neck cancers [1,2]. The vast majority are squamous
cell carcinomas; non-squamous histologies are rare. In
a retrospective review of 220 nasal and paranasal sinus
carcinomas, the most frequent histologic type was squa-
mous cell carcinoma (126 patients), followed by adenoid
cystic carcinoma (35), undifferentiated carcinoma (30) and
adenocarcinoma (25); only four were mucoepidermoid
carcinomas (MEC) [1].
Histologically, MECs include at least three cell types:
epidermoid cells, mucous cells and intermediate cells
[3,4]. MECs usually originate in the major salivary glands
of the head and neck but may also develop in any of
the 500–1000 minor salivary glands lining the upper
aerodigestive tract, including the oral cavity, pharynx,
larynx, nasal cavity and paranasal sinuses [5]. MECs
are reported within paranasal sinuses [1,4,6-8], but they
remain extremely rare [2-4], and are often grouped with
non-squamous carcinomas of different histologic types,
grades and sites. This makes it difficult to summarize the* Correspondence: Horia.vulpe@rmp.uhn.on.ca
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stated.characteristics, epidemiology and behaviour of paranasal
sinus MECs as a distinct entity.
In general, paranasal sinus malignancies of all histologies
are more common in males (1.6-2.0:1; M:F) and the
median age of diagnosis is between 50–70 years of age
[1,2]. These tumours usually present with advanced stage
because expansion within the air-filled sinuses typically
causes nonspecific symptoms such as pain, a palpable
mass, congestion, swelling, dysphagia and epistaxis
[1,2,7,9,10]. All histologic types combined, malignancies
of the paranasal sinuses present with locally advanced
T3/4 disease in 70-88% of cases [1,2]. Data on the
distinct presentation of MECs is sparse because they
are often pooled with other salivary gland tumours. There
is nevertheless some evidence that they are diagnosed
equally late. Bhattacharyya extracted 15 cases of maxillary
sinus MEC from the Surveillance, Epidemiology, and End
Results (SEER) database and found that 80% presented at
advanced tumour stage [11]. Dulguerov et al. report that
glandular carcinomas of the maxillary sinus (35 adenoid
cystic and four MECs) presented with T3/4 disease 70.3%
of the time [1].
Once diagnosed, the large size of the tumour puts it in
proximity of vital structures such as the eye, optic nerve,
cavernous sinuses and brain. Achieving negative surgical
margins may be technically difficult and, in incurable cases,td. This is an Open Access article distributed under the terms of the Creative
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external radiation therapy. We report here on a case of
maxillary sinus MEC which displayed impressive radio-
sensitivity to low, palliative doses of radiation therapy.
Case presentation
An 84 year old lady was referred to a local otolaryngolo-
gist-head and neck surgeon for a history of epistaxis,
occasional hemoptysis, difficulty swallowing, and a fetid
odor. She denied pain or significant distress related to
these symptoms. She did not drink, smoke or have any
known family history of cancer.
Her medical history included resection of a maxillary
sinus mass 45 years prior, in a different country. The
patient was unaware of the diagnosis and her previous
medical records could not be obtained. The prior surgery
left her with a surgical defect in the hard palate.
On presentation, her physical exam revealed numbness
in the left V2 distribution as well as left sided proptosis.
Extra-ocular movements were normal and palpation of
the neck did not reveal any lymphadenopathy. Oral and
endoscopic examinations showed a surgical defect in the
left hard palate extending into the maxillary sinus and
a mass visible in the left nasal cavity and maxillary
sinus. The remainder of the upper aerodigestive tract
was unremarkable.
Computed tomography of the head and neck revealed
a large heterogeneous and vascular mass at the center
of the left maxillary sinus with destruction of the medial,
inferior and lateral walls; destruction of the left side of
the hard palate; infiltration of the pterygopalatine fissure
and infratemporal fossa as well as extension into the nasal
cavity. The tumour extended into the left ethmoid air
cells, breaching the medial wall of the orbit but remained
extraconal, without intracranial extension (Figure 1).Figure 1 Coronal head and neck computed tomography (left) and ma
at presentation.MRI further demonstrated mass effect on the ocular
musculature causing proptosis and bilateral prominent
retropharyngeal nodes suspicious for nodal metastases.
The maximum diameter of the mass was 6.5 cm. There
was no evidence of distant metastasis on systemic staging.
Pathologic examination of the biopsy specimen demon-
strated small cysts lined by numerous mucous cells, large
numbers of polygonal clear cells and smaller intermediate
cells with round nuclei and small nucleoli (Figure 2).
These findings were consistent with an intermediate grade
(II/III) mucoepidermoid carcinoma.
The patient’s case was presented at multidisciplinary
rounds and based on the extent of disease, patient
performance status and the morbidity related to surgical
resection the consensus was not to recommend curative
surgery. Rather, the recommendation was for palliative
endoscopic debulking to improve proptosis as well as
palliative radiation therapy either as an alternative or in
conjunction with endoscopic debulking. The patient
declined initial treatment but then opted for radiotherapy
alone 18 months later when bleeding from the tumour
became unmanageable.
She received 700 cGy to the tumour using a right an-
terior oblique and left posterior oblique conformal beam
arrangement (Figure 3). Within one week she achieved
complete cessation of bleeding, decrease in bulk of
her tumour and improved eating. She continued to
have some discomfort from the lesion and underwent
a second fraction of 700 cGy seven days later. This
second fraction used a left lateral, right lateral and
right anterior oblique beam arrangement to limit dose
the brainstem and optic chiasm. The lenses were largely
avoided to prevent morbidity from pain and dry eyes.
Estimated cumulative maximal doses to organs at risk
were 909 cGy to the brainstem, 1073 cGy to the opticgnetic resonance imaging (right) showing tumour size
Figure 2 Left: Intermediate grade mucoepidermoid carcinoma showing small cysts lined by numerous mucous cells (H&E stain, 200X).
Right: Intermediate grade mucoepidermoid carcinoma composed of large numbers of polygonal clear cells and smaller intermediate cells with
round nuclei and small nucleoli (H&E stain and, 200X).
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eye, 266 cGy to the left lens and 379 cGy to the right
lens. Bleeding did not recur and her capacity to swallow
improved as the mass shrunk in size. Given the excellent
palliative result, a third planned fraction was not delivered.
Her only side-effect from radiation was mild mucositis,
which resolved within two weeks.
Follow-up CT two years later revealed a tumour clearly
smaller in size measuring 4.5 cm. It abutted the floor of
the left orbit, which had been previously displaced and
infiltrated by tumour (Figure 4). There were no suspicious
lymph nodes. At last follow-up, a little more than fourFigure 3 First radiation treatment plan showing isodose distribution
to the gross tumour volume (yellow isodose line) using right anterior obliqyears following completion of radiation therapy, the
patient did not have any evidence of progression of her
tumour. She continued to have eating difficulties due
to the palatal defect which no longer was filled with
tumour, but declined to use an obturator. Gastrostomy
tube insertion was attempted but subsequently removed
at the patient’s request. She maintains caloric intake with
liquid nutritional supplements.
Discussion
Loco-regional control remains of crucial importance in
incurable cases of head and neck cancer. Tumour extensionon axial, coronal and sagittal images. The patient received 700 cGy
ue and left posterior oblique conformal beam arrangement.
Figure 4 Sequential computed tomography between September 2007 and November 2011 showing decrease in tumour size after a
short course of radiation therapy delivered in June 2009.
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can be extremely morbid causing impairment in basic
human functions and significant disfigurement. Palliative
radiation therapy (RT) aims to improve symptoms related
to locoregional tumour spread while potentially slowing
or halting tumour progression. Because both RT and the
patient’s malignancy may cause debilitating side-effects, it
can be difficult to find balance between improving quality
of life and causing further symptoms such as pain,
mucositis and dysphagia. For this reason palliative
radiation regimens for head and neck cancer are indi-
vidualized to each patient based on factors such as
performance status and life expectancy [10].
A variety of radiation schedules exist but optimal
dose and fractionation scheme remain to be elucidated.
Although several trials and reviews have studied palliative
radiation therapy regimens in head and neck cancers
[9,12-14], these usually contain few, if any, MECs. Chen
et al. analyzed 60 patients with SCC of the head and neck
treated with various palliative RT regimens and found
that the RTOG 85–02 schedule (4440 cGy using 370 cGy
fractionation, administered twice a day for 2 consecutive
days at 2- to 3-week intervals for 3 total cycles) was associ-
ated with the least toxicity, while being equally effective.Whether this also applies to MECs is unclear and there
is generally little consensus on the radiosensitivity of this
tumour [15-17]. There is emerging evidence that MECs
may exhibit better response to radiation therapy than
previously thought in both the curative and palliative
setting. A retrospective review from the Princess Margaret
Hospital analyzed patients treated with palliative RT
to the head and neck and found that patients with
non-squamous histologies (including five MECs) had
increased overall survival (OS) as compared to SCC
(HR 0.52 CI: 0.28–0.96) [10]. In a large retrospective
review of 220 patients with nasal and paranasal sinus
carcinomas, 5-year carcinoma specific actuarial survival
was 79% for patients with glandular carcinoma (mucoepi-
dermoid and adenoid cystic) versus 60% for those with
squamous cell carcinoma [1]. A Japanese case report
describes a MEC of the larynx that completely responded
to curative doses of RT [18].
To our knowledge this is the first case report of a
MEC treated with low, palliative doses of radiotherapy,
resulting in partial response and long term control for
more than four years. This report contributes to the
small amount of existing evidence that MECs may be
particularly radiosensitive. Consideration should be given
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patients with locally advanced disease who are not suit-
able for curative treatment, as even low doses may lead
to palliation of symptoms and sustained tumor control.
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